Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 12/20 | 0.53 |
| ▸ | DRD3 | P35462 | 12/20 | 0.53 |
| ▸ | DRD4 | P21917 | 9/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30042139 | 0.93 | HRH4 (0.54) | HRH4DRD2DRD3DRD4IDO1 | |
| Formic Acid SCHEMBL25173916 | 0.93 | HRH4 (0.54) | HRH4DRD2DRD3DRD4IDO1 | |
| SCHEMBL30040533 | 0.88 | DRD4 (0.64) | HRH4DRD2DRD3DRD4IDO1 | |
| SCHEMBL23964238 | 0.88 | DRD4 (0.64) | HRH4DRD2DRD3DRD4IDO1 | |
| SCHEMBL23964200 | 0.86 | HRH4 (0.63) | HRH4DRD2DRD3DRD4HTR1A | |
| SCHEMBL30041451 | 0.86 | HRH4 (0.63) | HRH4DRD2DRD3DRD4HTR1A | |
| SCHEMBL8682915 | 0.85 | HRH4 (0.69) | HRH4DRD2DRD3DRD4HTR1A | |
| SCHEMBL30041328 | 0.85 | HRH4 (0.69) | HRH4DRD2DRD3DRD4HTR1A | |
| SCHEMBL23964207 | 0.82 | HRH4 (0.59) | HRH4DRD2DRD3DRD4HTR1A | |
| SCHEMBL23964212 | 0.81 | HRH4 (0.57) | HRH4DRD2DRD3DRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2021216665-A9 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021216665-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150980-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | HRH4 4471/4885DRD2 4780/4885DRD3 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.